Ranibizumab
- Generic Name
- Ranibizumab
- Brand Names
- Byooviz, Cimerli, Lucentis, Susvimo, Ranivisio, Rimmyrah, Ximluci
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 347396-82-1
- Unique Ingredient Identifier
- ZL1R02VT79
- Background
Ranibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment directed against human vascular endothelial growth factor A (VEGF-A), which is a glycoprotein implicated in the pathophysiology of age-related macular degeneration. Ranibizumab is used to treat various ocular disorders with abnormal growth of blood vessels, such as neovasc...
- Indication
Ranibizumab injection for intravitreal use is indicated to treat Neovascular (wet) Age-related Macular Degeneration (AMD), macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization.
...
- Associated Conditions
- Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), Macular Edema, Myopic Choroidal Neovascularization, Neovascular Age-Related Macular Degeneration (nAMD)
- Associated Therapies
- -
Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD
- First Posted Date
- 2007-07-11
- Last Posted Date
- 2014-10-06
- Lead Sponsor
- OPKO Health, Inc.
- Target Recruit Count
- 338
- Registration Number
- NCT00499590
- Locations
- 🇺🇸
Retina Institute of California (site 207), Pasadena, California, United States
🇺🇸Miramar Eye Specialists Medical Group (site 245), Ventura, California, United States
🇺🇸Florida Eye Microsurgical Institute, Inc. (site 217), Boynton Beach, Florida, United States
Lucentis for Inflammatory Macular Edema Trial
- First Posted Date
- 2007-07-10
- Last Posted Date
- 2017-11-30
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 7
- Registration Number
- NCT00498355
- Locations
- 🇺🇸
Proctor Foundation, UCSF, San Francisco, California, United States
Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL)
- Conditions
- Interventions
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2011-06-02
- Lead Sponsor
- QLT Inc.
- Target Recruit Count
- 162
- Registration Number
- NCT00492284
- Locations
- 🇺🇸
Retina Centers, PC, Tucson, Arizona, United States
Reduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular Degeneration
- Conditions
- Interventions
- First Posted Date
- 2007-05-15
- Last Posted Date
- 2020-11-06
- Target Recruit Count
- 31
- Registration Number
- NCT00473642
- Locations
- 🇺🇸
Eagle Mountain Vision, Tulsa, Oklahoma, United States
A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RIDE)
- Conditions
- Interventions
- First Posted Date
- 2007-05-15
- Last Posted Date
- 2017-04-17
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 382
- Registration Number
- NCT00473382
A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RISE)
- Conditions
- Interventions
- First Posted Date
- 2007-05-15
- Last Posted Date
- 2017-04-17
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 377
- Registration Number
- NCT00473330
EXTEND III - Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)
- Conditions
- Interventions
- First Posted Date
- 2007-05-08
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 95
- Registration Number
- NCT00470678
- Locations
- 🇨🇳
Novartis Investigative Site, LinKou, Taiwan
🇨🇳Novartis Investigative site, Taipei, Taiwan
A Study of Genetic and Environmental Factors and Their Effect on Response to Treatment With Lucentis (Ranibizumab) for Wet AMD
- Conditions
- First Posted Date
- 2007-05-04
- Last Posted Date
- 2011-07-22
- Lead Sponsor
- Oregon Health and Science University
- Target Recruit Count
- 150
- Registration Number
- NCT00469352
- Locations
- 🇺🇸
Casey Eye Institute, Oregon Health and Science University, Portland, Oregon, United States
Injected Ranibizumab to Treat Macular Telangiectasia With New Blood Vessel Formation
- Conditions
- First Posted Date
- 2007-04-05
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- National Eye Institute (NEI)
- Target Recruit Count
- 5
- Registration Number
- NCT00457067
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Injected Ranibizumab to Treat Macular Telangiectasia Without New Blood Vessel Formation
- Conditions
- First Posted Date
- 2007-04-05
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- National Eye Institute (NEI)
- Target Recruit Count
- 5
- Registration Number
- NCT00457145
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.